Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Hilpert

Showing results (31-40 of 107) with videos related to

Pageof 11
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 15, 2014
Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5)Günter Emons, Grigor Gorchev, Philipp Harter, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|January 16, 2013
Evaluation of two different vacuum-assisted breast biopsy systems: Mammotome(R) system 11G/8G vs. ATEC(R) system 12G/9GBerndt-Michael Order, Philipp J Schaefer, G Peters, et al.
Histopathology|September 17, 2013
Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case reviewStefan Kommoss, Cyril Blake Gilks, Friedrich Kommoss, et al.
The Lancet. Oncology|March 9, 2016
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trialChristina H Ruhlmann, Thomas Broe Christensen, Line Hammer Dohn, et al.
Translational Oncology|June 5, 2013
Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patientsDirk O Bauerschlag, Felix Hilpert, Werner Meier, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 16, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovaryRosalind M Glasspool, Antonio González Martín, David Millan, et al.
Anticancer Research|May 27, 2004
Electrofusion generates diverse DC-tumour cell hybrids for cancer immunotherapyJan B Weise, Felix Hilpert, Axel Heiser, et al.
Cancer Letters|July 11, 2012
Mammary fibroblasts regulate morphogenesis of normal and tumorigenic breast epithelial cells by mechanical and paracrine signalsInke Lühr, Andreas Friedl, Thorsten Overath, et al.
International Journal of Cancer|December 11, 2012
High expression of crystallin αB represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs TRAIL- and cisplatin-induced apoptosis in human ovarian cancer cellsJuliane Volkmann, Ute Reuning, Martina Rudelius, et al.
Physical Chemistry Chemical Physics : PCCP|June 5, 2025
How the ionic liquid [C<sub>2</sub>C<sub>1</sub>Im][OTf] affects the stability of Pt(111) during potential cyclingFelix Hilpert, Yunsheng Qiu, Leopold Lahn, et al.
Pageof 11

Showing results (31-40 of 107) with videos related to

Sort By:
Pageof 11
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 15, 2014
Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5)Günter Emons, Grigor Gorchev, Philipp Harter, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|January 16, 2013
Evaluation of two different vacuum-assisted breast biopsy systems: Mammotome(R) system 11G/8G vs. ATEC(R) system 12G/9GBerndt-Michael Order, Philipp J Schaefer, G Peters, et al.
Histopathology|September 17, 2013
Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case reviewStefan Kommoss, Cyril Blake Gilks, Friedrich Kommoss, et al.
The Lancet. Oncology|March 9, 2016
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trialChristina H Ruhlmann, Thomas Broe Christensen, Line Hammer Dohn, et al.
Translational Oncology|June 5, 2013
Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patientsDirk O Bauerschlag, Felix Hilpert, Werner Meier, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 16, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovaryRosalind M Glasspool, Antonio González Martín, David Millan, et al.
Anticancer Research|May 27, 2004
Electrofusion generates diverse DC-tumour cell hybrids for cancer immunotherapyJan B Weise, Felix Hilpert, Axel Heiser, et al.
Cancer Letters|July 11, 2012
Mammary fibroblasts regulate morphogenesis of normal and tumorigenic breast epithelial cells by mechanical and paracrine signalsInke Lühr, Andreas Friedl, Thorsten Overath, et al.
International Journal of Cancer|December 11, 2012
High expression of crystallin αB represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs TRAIL- and cisplatin-induced apoptosis in human ovarian cancer cellsJuliane Volkmann, Ute Reuning, Martina Rudelius, et al.
Physical Chemistry Chemical Physics : PCCP|June 5, 2025
How the ionic liquid [C<sub>2</sub>C<sub>1</sub>Im][OTf] affects the stability of Pt(111) during potential cyclingFelix Hilpert, Yunsheng Qiu, Leopold Lahn, et al.
Pageof 11